InspireMD Receives Listing Deficiency Letter from NYSE AMERICAN

Biotech Investing

InspireMD announced it received a letter from the NYSE American exchange on August 17 saying the company does not meet a listing standard.

InspireMD (NYSEMKT:NSPR) announced it received a letter from the NYSE American exchange on August 17 saying the company does not meet a listing standard.
As quoted in the press release:

InspireMD does not meet a certain NYSE American LLC (the “NYSE American”) continued listing standard as set forth in Part 10, Section 1003(a)(iii) of the Company Guide of the NYSE American, due to the fact the Company had reported stockholders’ equity of less than $6 million as of June 30, 2017 and had net losses in its five most recent fiscal years ended December 31, 2016. The Exchange’s notice has no immediate effect on the listing of the Company’s common stock on the Exchange. The Company’s management is reviewing its options to address the deficiency and expects to submit a compliance plan to the NYSE American on or before September 17, 2017, the deadline set by the Exchange, addressing how it intends to regain compliance with Sections 1003(a)(iii) of the Company Guide by February 17, 2019.

Click here to read the full press release.

Source: www.marketwired.com

The Conversation (0)
×